- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01157715
A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD (AURORA)
A Randomized, Double-masked, Multicenter, Controlled Dose- and Interval-ranging Clinical Study of Intravitreal Injection of KH902 in Patients With Neovascular Age-related Macular Degeneration (the AURORA Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
AMD is the leading cause of severe vision loss in people over the age of 65 in the United States and other western countries. A quantity of documents indicate that neovascularization promoted by VEGF is main cause of visual acuity decline. Patients are starving for a new drug which can notably improve VA with less administration frequency and lower treatment cost.
The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein. The pre-clinical researches and phase I study show that KH902 is effective and safe in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF.
This study is designed to confirm the efficacy and safety of multiple injections of KH902 at variable dosing regimen in patients with CNV due to neovascular AMD. Based on the characteristics of KH902 and results from KH902 Phase I study as well as reference to clinical trials of similar drugs, it is determined that KH902 is administrated at 0.5mg/eye/time and 2.0mg/eye/time.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Peking, China, 100044
- Peking University People's Hospital
-
Peking, China, 100730
- PekingTongren Hospital
-
Shanghai, China, 200080
- Shanghai First People's Hospital
-
Shanghai, China, 200031
- Eye & ENT Hospital of Fudan University
-
-
Fujian
-
Wenzhou, Fujian, China, 325027
- Optometry and Ophthalmology Hospital of Wenzhou Medical College
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Zhongshan Ophthalmic Center, Sun-Yat University
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Second Affiliated Hospital of Xiangya Medical College
-
-
Shanxi
-
Xian, Shanxi, China, 710032
- Xijing Hosiptal of the Fourth Military Medical University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Sichuan University West China Hospitcal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Signed the ICF; Age ≥ 50 years of either gender;
- Active primary or recurrent lesions with subfoveal or juxtafoveal CNV secondary to neovascular AMD in the study eye;
- Lesion size ≤ 12 disc areas in either eye;
- BCVA of the study eyes between 73 and 24 letters, inclusively, and the BCVA of fellow eyes ≥ 19 letters;
- Clear ocular media and adequate pupil dilation.
- If both eyes were eligible, only one was selected.
Exclusion criteria:
- History of vitreous hemorrhage, retinal detachment or macular hole, presence of retinal pigment epithelial tear, retinal macular traction or macular epiretinal membrane in the study eye;
- Subfoveal scar or atrophy in the study eye;
- Subretinal hemorrhage in the study eye;
- Uncontrolled glaucoma in either eye;
- Active inflammation or infection in either eye;
- Previous drug treatment, either anti-VEGF drugs or steroid derivatives, and/or, previous ophthalmologic operation or laser therapy in the study eye;
- History of surgery within one month preceding enrollment;
- Any uncontrolled clinical disorders;
- Patients of child-bearing potential do not adopted adequate contraception methods;
- Pregnant or nursing women;
- Patients need to exclude in the opinion of investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 0.5 mg cohort
patients will receive monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii.
prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
|
|
Experimental: 2.0 mg cohort
patients will receive monthly intravitreal injections of 2.0 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii.
prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in BCVA
Time Frame: at 3-month
|
at 3-month
|
The incidence rate of adverse event
Time Frame: at 3-month
|
at 3-month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in central retinal thickness
Time Frame: at 3-month and 12-month
|
at 3-month and 12-month
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xiaoxin Li, MD, Prof., Peking University People's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KHSWKH902001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Iconic Therapeutics, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
Clinical Trials on intravitreal injection of KH902
-
Chengdu Kanghong Biotech Co., Ltd.University of Wisconsin, Madison; Air Force Military Medical University, ChinaCompletedNeovascular Age-related Macular DegenerationChina
-
Chengdu Kanghong Biotech Co., Ltd.Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityRecruiting
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Jeffrey S HeierKato Pharmaceuticals, Inc.CompletedVitreomacular Traction | Vitreomacular Adhesion | Vitreomacular AttachmentUnited States
-
Xun XuPeking University; Zhongshan Ophthalmic Center, Sun Yat-sen University; Air Force... and other collaboratorsUnknownAge-Related Macular Degeneration | Polypoidal Choroidal Vasculopathy | Pathological Myopia | Conbercept | PharmacogenomicChina
-
Instituto Universitario de Oftalmobiología Aplicada...University of ValladolidActive, not recruitingNon Arteritic Ischemic Optic NeuropathySpain
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityCompletedNeovascular GlaucomaChina
-
Afyonkarahisar Health Sciences UniversityCompleted
-
Innovent Biologics (Suzhou) Co. Ltd.SuspendedDiabetic Macular Edema | Neovascular Age-related Macular DegenerationChina
-
Hemera BiosciencesWithdrawnGeographic Atrophy | Dry Age-related Macular Degeneration | Gene Therapy | Intravitreal Injection